Loading…
Reported covered position: Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Biosimilars Access and Affordability Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
UNITED THERAPEUTICS CORPORATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to organs and xenotransplantation.
Filing targets: HOUSE OF REPRESENTATIVES
PATIENT SQUARE CAPITAL via TIBER CREEK GROUP
2026 · third_quarter · Q3
Source: Senate LDA
| ELEVANCE HEALTH, INC. |
| 22 |
| 2021–2026 |
| EMD SERONO, INC. | 22 | 2021–2026 |
| MERCK & CO., INC. | 22 | 2021–2026 |
| NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU) | 22 | 2021–2026 |
| PHLOW CORPORATION | 22 | 2021–2026 |
| SIEMENS HEALTHINEERS | 22 | 2021–2026 |
| THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) | 22 | 2021–2026 |
| TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY | 22 | 2021–2026 |
| ACADIA PHARMACEUTICALS INC | 21 | 2021–2026 |
| PHRMA | 21 | 2022–2026 |
| INCYTE CORPORATION | 20 | 2021–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 20 | 2021–2026 |
| ASTRAZENECA | 18 | 2022–2026 |
| Alnylam Pharmaceuticals, Inc. | 16 | 2023–2026 |
| GILEAD SCIENCES, INC. | 16 | 2023–2026 |
| VERTEX PHARMACEUTICALS | 16 | 2022–2025 |
| ASTELLAS PHARMA US, INC. | 15 | 2023–2026 |
| MMM HEALTHCARE | 15 | 2021–2024 |
| AGILON HEALTH, INC. | 14 | 2023–2026 |
| ACCOUNTABLE FOR HEALTH | 13 | 2023–2026 |
| BRISTOL MYERS SQUIBB | 13 | 2021–2024 |
| DAIICHI SANKYO INC | 12 | 2024–2026 |
| MODIVCARE SOLUTIONS, LLC | 12 | 2021–2024 |
| PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 12 | 2024–2026 |
| DH DIAGNOSTICS, LLC | 10 | 2024–2026 |
| MYRIAD GENETICS INC | 10 | 2024–2026 |
| DELFI DIAGNOSTICS | 9 | 2022–2024 |
| RECORA | 9 | 2023–2025 |
| HUMANA, INC. | 8 | 2025–2026 |
| SOLVENTUM CORPORATION | 8 | 2025–2026 |
| SMITHS GROUP PLC | 7 | 2021–2022 |
| CORMEDIX, INC. | 6 | 2023–2024 |
| CORROHEALTH, INC. | 6 | 2025–2026 |
| INFUSYSTEMS HOLDINGS, INC. | 6 | 2021–2022 |
| ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS | 5 | 2025–2026 |
| PATIENT SQUARE CAPITAL | 5 | 2025–2026 |
| UNITED THERAPEUTICS CORPORATION | 4 | 2025–2026 |
| ANIVIVE LIFESCIENCES INC. | 3 | 2023–2024 |
| ICKES & ENRIGHT GROUP (NORTHWELL HEALTH FKA NORTH SHORE-LIJ) | 3 | 2022 |
| MCDERMOTT WILL & EMERY LLP (OBO ALNYLAM PHARMACEUTICALS) | 3 | 2022–2023 |
| ABBVIE, INC. | 2 | 2026 |
| ZYMERGEN INC. | 2 | 2021 |
| DEFINIUM THERAPEUTICS | 1 | 2026 |
| MUSSALLEM CHD ALLIANCE | 1 | 2026 |
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Ensuring Community Access to Pharmacist Services Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: TIBER CREEK GROUP
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Ensuring Community Access to Pharmacist Services Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: TIBER CREEK GROUP
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Access to Prescription Digital Therapeutics Act of 2025
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: TIBER CREEK GROUP
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Access to Prescription Digital Therapeutics Act of 2025
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: TIBER CREEK GROUP
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025. Issues related to H.R. 7871/S. 1637 - MVP Act.
Access to Prescription Digital Therapeutics Act of 2025
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: TIBER CREEK GROUP
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Improving Seniors’ Timely Access to Care Act of 2025
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to NIH/NCI funding; Issues related to H.R. 3514/S. 1816 - Improving Seniors Timely Access to Care Act of 2025.
Resident Physician Shortage Reduction Act of 2025
Client: THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) · Firm: TIBER CREEK GROUP
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Resident Physician Shortage Reduction Act of 2025
Client: THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) · Firm: TIBER CREEK GROUP
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Resident Physician Shortage Reduction Act of 2025
Client: THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) · Firm: TIBER CREEK GROUP
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Resident Physician Shortage Reduction Act of 2025
Client: THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) · Firm: TIBER CREEK GROUP
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Resident Physician Shortage Reduction Act of 2025
Client: THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) · Firm: TIBER CREEK GROUP
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Resident Physician Shortage Reduction Act of 2025
Client: THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) · Firm: TIBER CREEK GROUP
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: ABBVIE INC. · Firm: TIBER CREEK GROUP
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: ABBVIE INC. · Firm: TIBER CREEK GROUP
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: ABBVIE INC. · Firm: TIBER CREEK GROUP
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to infectious disease diagnostics.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to point of care testing; Issues related to H.R. 7352 - PASTEUR Act of 2026.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025. Issues related to H.R. 7871/S. 1637 - MVP Act.
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Client: AGILON HEALTH, INC. · Firm: TIBER CREEK GROUP
Issues related to value-based health care, including Medicare Advantage (MA) and ACO models; Issues related to Medicare Shared Savings Program (MSSP); Issues related to the LEAD Model; Issues related to H.R. 9693 - Patients First Act of 2026, including APM bonus payments; Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program; Issues related to CMS innovation and payment model activities through CMMI.
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Client: AGILON HEALTH, INC. · Firm: TIBER CREEK GROUP
Issues related to value-based health care, including Medicare Advantage (MA) and ACO models; Issues related to Medicare Shared Savings Program (MSSP); Issues related to the ACO REACH Model; Issues related to the LEAD Model; Issues related to MA data sharing; Issues related to physician reimbursement and MACRA-related policies, including APM bonus payments; Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program; Issues related to CMS innovation and payment model activities through CMMI.
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Client: ACCOUNTABLE FOR HEALTH · Firm: TIBER CREEK GROUP
Issues related to value-based health care, including the Medicare Shared Savings Program (MSSP), ACO Reach Program and Comprehensive Kidney Care Contracting demonstration program; Issues related to physician reimbursement, including reforms to the Medicare Access and CHIP Reauthorization Act of 2015 (PL 114-10); Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program.
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Client: ACCOUNTABLE FOR HEALTH · Firm: TIBER CREEK GROUP
Issues related to value-based health care, including the Medicare Shared Savings Program (MSSP), ACO Reach Program and Comprehensive Kidney Care Contracting demonstration program; Issues related to physician reimbursement, including reforms to the Medicare Access and CHIP Reauthorization Act of 2015 (PL 114-10); Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program.
National Defense Authorization Act for Fiscal Year 2027
Client: PHLOW CORPORATION · Firm: TIBER CREEK GROUP
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
National Defense Authorization Act for Fiscal Year 2027
Client: ORGANON, LLC · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Servicemember Quality of Life Improvement; Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
ORPHAN Cures Act
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to value-based health care, including Medicare Advantage (MA) and ACO models; Issues related to Medicare Shared Savings Program (MSSP); Issues related to the LEAD Model; Issues related to H.R. 9693 - Patients First Act of 2026, including APM bonus payments; Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program; Issues related to CMS innovation and payment model activities through CMMI.
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Client: INCYTE CORPORATION · Firm: TIBER CREEK GROUP
Issues related to H.Res. 1331 - Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Client: INCYTE CORPORATION · Firm: TIBER CREEK GROUP
Issues related to H.Res. 1331 - Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Affordable Prescriptions for Patients Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Affordable Prescriptions for Patients Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Affordable Prescriptions for Patients Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Preserve Access to Affordable Generics and Biosimilars Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Issues related to telemedicine and the rural health transformation fund.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to brokers and the Medicare program.
Issues related to insurance coverage, ACA market reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORROHEALTH, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Advantage and Medicare Program Integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to protected health information; Issues related to S. 3097 - Health Information Privacy Reform Act; Issues related to the Health Insurance Portability and Accountability Act (HIPAA) (PL 104-191) Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AGILON HEALTH, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to value-based health care, including Medicare Advantage (MA) and ACO models; Issues related to Medicare Shared Savings Program (MSSP); Issues related to the LEAD Model; Issues related to H.R. 9693 - Patients First Act of 2026, including APM bonus payments; Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program; Issues related to CMS innovation and payment model activities through CMMI.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to NIH/NCI funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACCOUNTABLE FOR HEALTH via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to value-based health care, including the Medicare Shared Savings Program (MSSP), ACO Reach Program and Comprehensive Kidney Care Contracting demonstration program; Issues related to physician reimbursement, including reforms to the Medicare Access and CHIP Reauthorization Act of 2015 (PL 114-10); Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to drug pricing; Issues related to the Inflation Reduction Act (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to tariff policy and supply chain policy.
SOLVENTUM CORPORATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to immunization policy.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to intellectual property protections.
Issues related to immunization policy.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to H.Res. 1331 - Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to Health and Human Services Center for Medicare and Medicaid Innovation GUARD Demo; Issues related to Medicare coverage of Vitilligo.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DH DIAGNOSTICS LLC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to funding for diagnostics.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to infectious disease diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to domestic pharmaceutical production.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing; Issues related to S. 2658 - Medication Affordability and Patent Integrity Act.
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 (PL 118-159).
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to laboratory services covered under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUMANA, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to health care payment policy, including Medicare Advantage, Medicare Part D, and other payer policy matters, as well as health care clinical services; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via TIBER CREEK GROUP
2026 · third_quarter · RA
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
DEFINIUM THERAPEUTICS via TIBER CREEK GROUP
2026 · third_quarter · RR
Issues related to FDA approved Psychedelics; Issues related to DEA rescheduling of FDA approved products.
Issues related to FDA approved Psychedelics; Issues related to DEA rescheduling of FDA approved products.
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to drug pricing; Issues related to the Inflation Reduction Act (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DH DIAGNOSTICS LLC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026.
Issues related to funding for diagnostics.
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITED THERAPEUTICS CORPORATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to organs and xenotransplantation.
Filing targets: HOUSE OF REPRESENTATIVES
ACADEMY OF MANAGED CARE PHARMACY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025; Issues related to H.R. 7871/S. 1637 - MVP Act; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Ensuring Community Access to Pharmacist Services Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PATIENT SQUARE CAPITAL via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to telemedicine and the rural health transformation fund.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to brokers and the Medicare program.
Issues related to insurance coverage, ACA market reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to NIH/NCI funding; Issues related to H.R. 3514/S. 1816 - Improving Seniors Timely Access to Care Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORROHEALTH, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Advantage and Medicare Program Integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AGILON HEALTH, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to value-based health care, including Medicare Advantage (MA) and ACO models; Issues related to Medicare Shared Savings Program (MSSP); Issues related to the ACO REACH Model; Issues related to the LEAD Model; Issues related to MA data sharing; Issues related to physician reimbursement and MACRA-related policies, including APM bonus payments; Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program; Issues related to CMS innovation and payment model activities through CMMI.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACCOUNTABLE FOR HEALTH via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to value-based health care, including the Medicare Shared Savings Program (MSSP), ACO Reach Program and Comprehensive Kidney Care Contracting demonstration program; Issues related to physician reimbursement, including reforms to the Medicare Access and CHIP Reauthorization Act of 2015 (PL 114-10); Issues related to H.R. 8129 - To amend title XVIII of the Social Security Act to establish a full risk ACO program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to immunization policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Issues related to immunization policy.
Issues related to intellectual property protections.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to protected health information; Issues related to S. 3097 - Health Information Privacy Reform Act; Issues related to the Health Insurance Portability and Accountability Act (HIPAA) (PL 104-191) Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
INCYTE CORPORATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to H.Res. 1331 - Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to Health and Human Services Center for Medicare and Medicaid Innovation GUARD Demo.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLVENTUM CORPORATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Issues related to domestic pharmaceutical production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to IP protection under Bayh Dole; Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing.
Issues related to IP protection under Bayh Dole; Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing; Issues related to S. 2658 - Medication Affordability and Patent Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to women's health.
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Servicemember Quality of Life Improvement; Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027.
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to laboratory services covered under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUMANA, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to health care payment policy, including Medicare Advantage, Medicare Part D, and other payer policy matters, as well as health care clinical services; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to HIV prevention and procurement.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to tariff policy and supply chain policy.
MUSSALLEM CHD ALLIANCE via TIBER CREEK GROUP
2026 · second_quarter · RR
Activities related to Every 100th Heart.
SOLVENTUM CORPORATION via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to domestic pharmaceutical production.
Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to IP protection under Bayh Dole; Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing.
Issues related to IP protection under Bayh Dole; Issues related to implementation of drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 (PL 118-159)
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to laboratory services covered under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUMANA, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to health care payment policy, including Medicare Advantage, Medicare Part D, and other payer policy matters, as well as health care clinical services; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
DH DIAGNOSTICS LLC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Issues related to point of care testing; Issues related to H.R. 7352 - PASTEUR Act of 2026.
Issues related to funding for diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Issues related to tariff policy and supply chain policy.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
PATIENT SQUARE CAPITAL via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to telemedicine and the rural health transformation fund.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to insurance coverage, ACA market reforms, and telemedicine flexibilities; Issues related to the extension of Enhanced Advanced Premium Tax Credits (EAPTCs); Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORROHEALTH, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare Advantage and Medicare Program Integrity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to protected health information; Issues related to S. 3097 - Health Information Privacy Reform Act; Issues related to the Health Insurance Portability and Accountability Act (HIPAA) (PL 104-191) Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AGILON HEALTH, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to value-based health care, including the Medicare Shared Savings Program (MSSP) and the ACO Reach Program; Issues related to Medicare Advantage; Issues related to the extension of Alternative Payment Model bonus payments and physician reimbursement, including the Medicare Access and CHIP Reauthorization Act of 2015 (PL 114-10) and the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to Medicare payment demonstration projects.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ACCOUNTABLE FOR HEALTH via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to value-based health care; Issues related to reforming provider payments and the adoption of accountable care; Issues related to Medicare payment demonstration projects; Issues related to reforming payments for skin substitute treatments in the Calendar Year 2026 Medicare Physician Fee Schedule Rule; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to rare disease treatments, including rare disease research incentives; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
THE ICKES AND ENRIGHT GROUP (ON BEHALF OF GREATER NEW YORK HOSPITAL ASSOCIATION) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues impacting the hospital industry; Issues impacting hospital reimbursement; Issues related to workforce development and graduate medical education; Issues related to H.R. 3890/S. 2439 - Resident Physician Shortage Reduction Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to NIH/NCI funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to managed care pharmacists, including access to digital therapeutics and value-based care in Medicaid; Issues related to H.R. 3288/S. 1702 - Access to Prescription Digital Therapeutics Act of 2025. Issues related to H.R. 7871/S. 1637 - MVP Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to immunization policy.
Issues related to intellectual property protections; Issues related to tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to vaccine policy.
Issues related to intellectual property protections.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to women's health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to HIV prevention and procurement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to women's health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to HIV prevention and procurement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE